Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)

Centre Hospitalier Universitaire de Nīmes83 enrolled

Overview

Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness. Treatment: corticosteroid therapy, which is effective in the vast majority of cases. Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences: * Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity. * Requires additional immunosuppressive treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Giant Cell Arteritis Horton Disease

Interventions

no interventionOTHER

no intervention

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 45 years or older * Patients with giant cell arteritis according to ACR criteria or revised criteria incorporating imaging parameters, * Patients managed at the University Hospital of Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020. Exclusion Criteria: None

Outcomes

Primary Outcomes

Clinical and paraclinical characteristics of patients diagnosed with ACG

Describe the clinical and paraclinical characteristics of patients diagnosed with ACG to determine whether certain characteristics are significantly associated with a higher risk of developing corticosteroid dependence

Time frame: day 1